When the results were compared with studies in the literature using standard radiocolloid tracers the researchers found that the SN biopsy using tilmanocept
provided a high
identification rate and low
false negative rate for SNs, thus facilitating accurate prediction of the spread of the cancer.
Identification of those men at greatest risk for prostate cancer development and progression would
provide a means of targeted screening, thereby reducing unnecessary testing,
false positive tests, and the burden of overdiagnosis and over treatment.